207 results about "Autoantibody" patented technology

The invention discloses a fusion protein, a fusion protein gene, a recombinant cell, a recombinant antigen, a reagent for detecting an anti-myelin sheath related glycoprotein antibody and a preparation method, a detection method and application of the reagent, the fusion protein is MAG, GlcAT-P and HNK-1ST fusion protein, and the MAG, GlcAT-P and HNK-1ST fusion protein is formed by sequentially connecting MAG, a GGGGS sequence, EGFP, P2A, GlcAT-P, T2A and HNK-1ST; the amino acid sequence of the MAG, GlcAT-P and HNK-1ST fusion protein is as shown in SEQ ID NO. 1; the kit can be used for detecting the MAG autoantibody, has excellent detection sensitivity and specificity, and can ensure the detection accuracy especially for the detection in a low titer range.

The invention discloses a neutralizing nucleic acid aptamer for targeted inhibition of a B cell activating factor and application of the neutralizing nucleic acid aptamer in treatment of systemic lupus erythematosus. The neutralizing aptamer disclosed by the invention can be used for efficiently inhibiting the combination of BAFF and specific receptors on a B cell membrane, including a BAFF receptor (BAFF-R), a human calcium regulatory cyclophilin ligand interaction molecule (TACI) and a B cell maturation antigen (BCMA), so that the proportion of plasma cells, plasma mother cells and hair growth center B cells is reduced, and finally, the generation and secretion of autoantibodies are reduced; the compound has a targeted therapeutic effect on systemic lupus erythematosus. Compared with an existing biological agent for neutralizing BAFF, the neutralizing nucleic acid aptamer has the advantages of being high in specificity, high in affinity, easy to synthesize, low in immunogenicity, low in cost, capable of being designed and programmed and the like, is a potential novel nucleic acid preparation for SLE targeted therapy, and has a good clinical transformation application prospect.

The present disclosure provides systems and methods for detecting anti-NMDAR autoantibodies based on the strong affinity of the anti-NMDAR autoantibodies to a plurality of non-random anti-NR1s coupled to a solid support. The present disclosure also provides methods of treatment for anti-NMDAR pathology by the therapeutic anti-NMDAR antibody ART5803. The present disclosure also provides methods and systems for screening and predicting potential responsiveness to ART5803 therapy.

The invention relates to the technical field of liquid phase chips, in particular to an autoantibody spectrum detection platform based on a liquid phase chip technology, and the method comprises the following steps: preparation and functionalization of quantum dot encoding microspheres; the core-shell structure quantum dots are used as coding elements, and fluorescence coding combination of more than 1000 is realized by regulating and controlling the size, 3-10nm, Mn < 2 + > doping and spatial distribution of the quantum dots. The method has the advantages of super multi-target detection, super sensitivity, strong anti-interference capability and intelligent analysis, in the actual process, the core-shell structure quantum dots are adopted as coding elements, more than 1000 fluorescent coding combinations are realized by regulating and controlling the size, doping and spatial distribution of the quantum dots, high-density coding is realized by utilizing three-parameter coding and an orthogonal decoupling algorithm, and the method is suitable for large-scale industrial production. More types of autoantibodies can be detected at the same time, so that the detection flux is improved; the surfaces of the quantum dots are coated with silicon dioxide layers, and the fluorescence intensity is attenuated by lt under continuous laser irradiation; and the stability of a fluorescence signal in the detection process is ensured.

A method for characterizing disease activity in a systemic lupus erythematosus patient (SLE), comprising obtaining a dataset associated with a blood, serum, plasma or urine sample from the patient, assessing the dataset for a presence or an amount of protein expression of at least one innate serum or plasma mediator, assessing the dataset for a presence or an amount of protein expression of at least one adaptive serum or plasma mediator biomarker, assessing the dataset for a presence or an amount of at least one chemokine / adhesion molecule biomarker, assessing the dataset for a presence or an amount of at least one soluble TNF superfamily biomarker, assessing the dataset for a presence or an amount of at least one inflammatory mediator biomarker, assessing the dataset for a presence or an amount at least one SLE-associated autoantibody specificity biomarker and calculating a Lupus Disease Activity Immune Index (LDAII) score.

The present disclosure provides methods of treating an alloimmune or autoimmune disorder in an individual; the methods involve administering to the individual an effective amount of an antibody specific for complement component C1s. The present disclosure provides a method of monitoring the efficacy of a subject treatment method; the method involves detecting the level of autoantibody or alloantibody in a biological sample obtained from the individual.

The application belongs to the technical field of biomedical detection, and particularly relates to a biomarker for lung cancer diagnosis and application thereof. A new lung cancer biomarker anti-FDX1 autoantibody is found for the first time, and the expression level of the plasma anti-FDX1 autoantibody can be detected to distinguish lung cancer patients from normal people, and the experimental results also show that the anti-FDX1 autoantibody can be used as a detection index for different clinical characteristics of lung cancer. Further, the anti-FDX1 autoantibody is combined with carcinoembryonic antigen to construct a new lung cancer detection model as a marker, and experimental data show that the combined model can significantly improve the lung cancer detection efficiency, which has important significance for lung cancer diagnosis.

The present invention is directed to multispecific molecules that bind immunoglobulin and a recycling target. Binding immunoglobulin and a recycling target results in degradation of immunoglobulin and in certain embodiments recycling of the multispecific molecule. The multispecific molecules of the present invention are thought to be useful in the treatment of autoantibody-induced diseases.

The present disclosure generally relates to compositions and methods for predicting or diagnosing immune-related adverse events (irAE) before, during, or after immune checkpoint inhibitor (ICI) treatment in a subject with cancer. The method includes assessment of immune cell types, cytokines, autoantibodies or any combination thereof.

A method for determining the health status of an elderly individual by testing the sample extracted from the individual for the presence of biomarkers, the bio markers being autoantibodies to antigens comprising MAPK13, CD96, FKBP3, PPM1A, PHLDA1, GLRX3, FEN1 and AURKA, wherein the antigens may further comprise one or more of UBE2I, AAK1, YARS, ASPSCR1, CASP10, FHOD2, TCL1A and MAP4, wherein PHLDA1 and CD96 correspond to healthy, AURKA, FEN1, CASP10 and AAK1 correspond to intermediate health, and UBE2I, YARS, ASPSCR1, FHOD2, TCL1A, MAP4, MAPK13, FKBP3, PPM1A and GLRX3 correspond to unhealthy.

The present disclosure relates to human antibodies specific to dermatomyositis antigen peptides, preparation methods and uses. Specifically, the present disclosure relates to a monoclonal antibody that specifically binds to MDA5 antigen protein, a preparation method of the monoclonal antibody and a use of the aforementioned monoclonal antibody in the preparation of a drug for the diagnosis, prevention or treatment of inflammatory myopathy or its complications. The antibody or antigen-binding fragment against MDA5 screened by the present disclosure specifically binds to MDA5 antigen, can be used as a reference standard for qualitative detection of MDA5 positivity, realizes qualitative or quantitative detection of the level of anti-MDA5 autoantibody in patients with inflammatory myopathy or its complications, and has important significance for the clinical diagnosis, disease monitoring and treatment of patients with DM, CAMD, DM-ILD, CADM-ILD and the like.

This document relates to methods and materials involved in assessing and / or treating mammals having a caveolinopathy disease (e.g., immune-mediated rippling muscle disease (iRMD)). For example, methods and materials for detecting the presence of an autoantibody specific for a caveolae-associated protein 4 (cavin-4) polypeptide to identify a mammal as having iRMD as well as methods for treating a mammal identified having iRMD are provided. In some cases, cavin-4 polypeptides (and / or fragments thereof and / or variants thereof) can be used to detect the presence or absence of anti-cavin-4 polypeptide autoantibodies indicative of iRMD.

The application provides an autoantibody marker for predicting the effect of lung cancer immunneoadjuvant therapy on lung cancer patients in the third stage, a series of autoantibody marker molecules are screened by detecting autoantibodies against different antigen targets in blood of lung cancer patients in the third stage, and the autoantibody marker molecules have great correlation with the prediction of the effect of lung cancer immunneoadjuvant therapy, and three autoantibody biomarkers with better prediction of the effect of lung cancer immunneoadjuvant therapy on lung cancer patients in the third stage are further screened by combining with a CART decision tree strategy; the combination of the autoantibody biomarkers can be used for efficiently predicting whether the lung cancer immunneoadjuvant therapy on lung cancer patients in the third stage is effective, providing a reference basis for a clinician to decide a treatment scheme, providing a new prediction means for the effect of lung cancer immunneoadjuvant therapy on lung cancer patients in the third stage, and having important scientific significance and clinical application value.

The application provides a method for constructing an animal model of systemic lupus erythematosus, and the animal model of systemic lupus erythematosus shows high autoantibody, low complement, high inflammatory factor and severe kidney damage. The animal model of systemic lupus erythematosus provided by the application has a clear cause, can cause abnormalities of innate immunity and acquired immunity systems, and has a short experimental cycle, thereby providing a new animal model for drug candidate screening, drug treatment effect evaluation and pathogenesis research of systemic lupus erythematosus.

The present invention includes a method and kit for method for detecting anti-Ro antibody negative Sjögren's syndrome / Sjögren's disease without performing a lip biopsy comprising: obtaining a biological sample from a patient suspected of having an anti-Ro antibody negative Sjögren's syndrome / Sjögren's disease; and detecting if the biological sample has autoantibodies to at least one of: Geminin DNA Replication Inhibitor (GMNN), Kelch Domain Containing 8 A (KLHDC8A), Microtubule Associated Protein RP / EB Family Member 1 (MAPRE1), Nucleoporin 50 (NUP50), or SKI Like Proto-Oncogene (SKIL).

A method of diagnosing systemic lupus erythematosus using an antigen protein that binds specifically to an SMYD3 autoantibody present in body fluid of a patient with systemic lupus erythematosus. The diagnostic method uses a non-invasive biological sample such as blood, and thus may diagnose systemic lupus erythematosus very conveniently without burdening the patient, unlike conventional methods. In addition, the method has high specificity and sensitivity, and thus may be effectively used for early diagnosis of systemic lupus erythematosus.

The invention relates to a chimeric autoantibody receptor (CAAR) comprising an autoantigen of a Contactin-associated protein-like 2 (CASPR2) protein or one or more autoantigenic fragments thereof. The invention relates further to a nucleic acid molecule encoding a chimeric autoantibody receptor (CAAR), the nucleic acid comprising a sequence encoding an autoantigen, wherein said autoantigen comprises or consists of Contactin-associated protein-like 2 (CASPR2) or one or more fragments thereof, a sequence encoding a transmembrane domain, and a sequence encoding an intracellular signaling domain. The invention further relates to a nucleic acid vector comprising a nucleic acid molecule encoding the chimeric autoantibody receptor (CAAR) of the invention. The invention relates further to a genetically modified cell comprising a nucleic acid molecule or a vector of the invention and / or expressing a CAAR according to the invention.

Provided are a diagnostically useful carrier coated with a recombinant polypeptide comprising SEQ ID NO: 1, an isolated autoantibody binding specifically to a polypeptide having SEQ ID NO: 1, a kit comprising the carrier, a method for the diagnosis of a membranous nephropathy (MN) that includes detecting the presence or absence of an autoantibody binding specifically to a polypeptide having SEQ ID NO: 1 in a liquid sample comprising antibodies from a subject, a use of an autoantibody binding specifically to a polypeptide having SEQ ID NO: 1 or a polypeptide comprising SEQ ID NO: 1, and a aqueous solution comprising an autoantibody binding specifically to a polypeptide having SEQ ID NO: 1.

The invention belongs to the technical field of bioengineering, and particularly discloses GPIb alpha CAAR, GPIb alpha CAAR plasmids, GPIb alpha CAAR-Treg, a construction method of the GPIb alpha CAAR-Treg and application of the GPIb alpha CAAR-Treg to treatment of immune thrombocytopenia. The invention relates to GPIb alpha CAAR and a preparation method and application thereof on one hand, relates to GPIb alpha CAAR plasmids and a preparation method and application thereof on the other hand, and further relates to GPIb alpha CAAR-Treg and a preparation method and application thereof. According to the present invention, by constructing the regulatory T cell (Treg) expressing the GPIb alpha chimeric autoantibody receptor (CAAR), the specific recognition and inhibition of the pathogenic B cell secreting the anti-GPIb alpha antibody are achieved, such that the generation of the key pathogenic antibody in the ITP is blocked from the source;

The present disclosure relates to the field of clinical detection technology, in particular, to the application of triiodothyronine autoantibody as a marker of thyroid dysfunction during cancer treatment. The present disclosure can help clinicians to judge the real thyroid function status of patients and improve the accuracy of diagnosis.

The present disclosure provides inter alia, molecules comprising an autoantibody-binding domain and at least one modified Fc domain. The present disclosure also provides methods and compositions that allow for selective depletion and / or neutralization of pathogenic autoantibodies.

The application discloses a systemic sclerosis biomarker and application thereof, and belongs to the biomarker field. The application takes TTLL7-IT1 / miR-29c-3p / GLS as a combination for SSc diagnosis, and the core advantage lies in upgrading from a "isolated molecular marker" to a "functional pathological axis", realizing double breakthroughs of diagnostic sensitivity and mechanism specificity. Compared with existing single autoantibody (such as anti-Scl-70) or inflammatory index, the combination has significant potential in early diagnosis, subtype differentiation and activity evaluation.

Methods of preparing therapeutic blood products from merged plasma donors are described. Therapeutic blood products include, for example, plasma, plasma proteins, and plasma fractions with improved safety by reducing the concentration of donor autoantibodies against Fc [epsilon] RI [beta] or eliminating such antibodies.

The application belongs to but is not limited to the field of biomedical technology, and discloses application of anti-ACSL6 autoantibody as a prognostic evaluation marker for lung adenocarcinoma. Compared with traditional markers, the circulating biomarker anti-ACSL6 autoantibody has the characteristics of specificity, stability, early production, non-invasiveness, easy detection and the like, and has more potential value in reflecting the prediction of patient prognosis. High expression of anti-ACSL6 autoantibody is often related to poor survival of LUAD patients, and patients with low expression show relatively better prognosis. And anti-ACSL6 autoantibody remains significant in multivariate Cox regression, indicating that it can independently predict the survival outcome of patients after adjusting various confounding factors such as gender, age, stage, metastasis status and the like. This enables anti-ACSL6 autoantibody to provide more accurate risk stratification basis for clinicians, and help to develop individualized treatment and follow-up plans.

This invention provides a serum protein biomarker for early screening and diagnosis of pancreatic ductal adenocarcinoma. The serum protein biomarker is one or a combination of two or more autoantibodies against tumor-associated antigens HEXB, TXLNA, and SLAMF6. The invention also provides the application of reagents, kits, and analytical methods for detecting the serum protein biomarker. This invention screens for autoantibodies against pancreatic ductal adenocarcinoma-associated antigens. By measuring the expression levels of these indicators in the serum of patients with pancreatic ductal adenocarcinoma, healthy controls, and controls with benign pancreatic diseases, the screened anti-HEXB, anti-TXLNA, and anti-SLAMF6 autoantibodies can distinguish between pancreatic ductal adenocarcinoma, healthy controls, and benign pancreatic diseases. Furthermore, this invention designs and optimizes combinations of tumor-associated antigens for the diagnosis of pancreatic ductal adenocarcinoma. Applying the optimized antigens to an ELISA kit and detecting serum anti-TAA autoantibodies using an indirect enzyme-linked immunosorbent assay (ELISA) can accurately identify patients with pancreatic ductal adenocarcinoma, healthy controls, and patients with benign pancreatic diseases.

Materials and methods are provided herein for detecting the presence of an autoantibody specific for PDE10A to identify the mammal as having an autoimmune neurological disorder as well as methods and materials for treating an autoimmune neurological disorder. Materials and methods also are provided herein for treating cancer and / or neurological autoimmunity in a mammal using an immune checkpoint inhibitor and detecting the presence of an autoantibody specific for PDE10A to monitor for the development of neurologic complications in the mammal.

The utility model discloses a kit for detecting M-type phospholipase A2 receptor autoantibody, which relates to the technical field of biological detection and comprises a kit body, a drawing box is slidably connected in the kit body, an empty slot is arranged at the top end of the kit body, a placing box is slidably connected in the empty slot, the top end of the placing box is rotatably connected to a kit cover, and the drawing box is arranged in the box cover. A placing groove is formed in the placing box, the limiting mechanism comprises a storage groove formed in the drawing box, fixing assemblies used for assisting in taking are fixedly connected to the two sides of the inner wall of the box body, and a clamping block is fixedly connected to one end of a spring rod; the taking mechanism is arranged in the box body, and the taking mechanism is used for assisting a worker to quickly take the stored detection antibody. The kit disclosed by the utility model has the effects that a user can conveniently take the test paper, and meanwhile, the test paper can be stored in a daily limiting manner.

Provided herein are compounds, including compounds of any of the formulae described herein (e.g., Formula (I'), Formula (I), Formula (II)), and pharmaceutically acceptable salts thereof. Compounds provided herein are capable of covalently binding to and inhibiting neonatal fragment crystallizable receptor (FcRn) proteins and are therefore useful in the treatment and / or prevention of various diseases, including conditions associated with FcRn activity and / or immunoglobulin G (IgG) autoantibody levels in a subject.

The invention provides a system for diagnosing Behcet's disease through expression quantity of a molecular marker, application of a reagent for quantitatively detecting the expression quantity of the molecular marker in preparation of a kit for diagnosing Behcet's disease, the kit for diagnosing Behcet's disease, application of the molecular marker in preparation of the kit for diagnosing Behcet's disease and application of the molecular marker in preparation of the kit for diagnosing Behcet's disease. The molecular marker comprises a combination of an AMT autoantibody, a PRSS8 autoantibody, a GJC3 autoantibody, a TAF15 autoantibody and an HIPK2 autoantibody. According to the technical scheme, the molecular marker with high specificity and high sensitivity and a curative effect prediction model are provided for diagnosis and treatment of Behcet's disease.